Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy

BACKGROUND: Anemia is more frequent in patients receiving telaprevir with PEGylated interferon/ribavirin (PEG-IFN/RBV) than in those receiving PEG-IFN/RBV alone. OBJECTIVES: The objective was to measure the impact of telaprevir on RBV bioavailability and to assess the concomitant renal function. MAT...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradat, Pierre, Virlogeux, Victor, Maynard, Marianne, Leclercq, Mathilde, Hatu, Giorgiana, Amiri, Majid, Lebosse, Fanny, Miailhes, Patrick, Zoulim, Fabien, Gagnieu, Marie-Claude, Bailly, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2015
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611953/
https://www.ncbi.nlm.nih.gov/pubmed/26500683
http://dx.doi.org/10.5812/hepatmon.28879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611953/
https://www.ncbi.nlm.nih.gov/pubmed/26500683
http://dx.doi.org/10.5812/hepatmon.28879

Ejemplares similares